Graft versus Host Disease (GvHD) - Market Insights, Epidemiology and Market Forecast - 2027

  • ID: 4473300
  • Drug Pipelines
  • 222 Pages
  • DelveInsight
1 of 5
The 7Mm Market of Graft Versus Host Disease (GvHD) was USD 353.5 Million in 2016, and is Expected to Increase at a CAGR from 2016-2027

FEATURED COMPANIES

  • AbbVie
  • CSL Behring
  • Enlivex Therapeutics
  • Incyte Corportaion
  • Kamada
  • Mallinckrodt
  • MORE

‘Graft versus Host Disease (GvHD) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of GvHD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Graft versus Host Disease (GvHD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Graft versus Host Disease (GvHD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Graft versus Host Disease (GvHD) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Graft versus Host Disease (GvHD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Graft versus Host Disease (GvHD) market
  • Organize sales and marketing efforts by identifying the best opportunities for Graft versus Host Disease (GvHD) market
  • To understand the future market competition in the Graft versus Host Disease (GvHD) market.

Please allow up to 48 hours for the delivery of this report once payment has been made.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • CSL Behring
  • Enlivex Therapeutics
  • Incyte Corportaion
  • Kamada
  • Mallinckrodt
  • MORE

1. Report Introduction

2. GvHD Market Overview at a Glance
2.1. Market Share Distribution of GvHD in 2017
2.2. Market Share Distribution of GvHD in 2027

3. Disease Background and Overview: Graft versus Host Disease (GvHD)
3.1. Introduction
3.2. Disease Types
3.3. Acute GvHD
3.4. Chronic GvHD
3.5. Grades of GvHD
3.6. Pathophysiology
3.7. Risk Factors for GVHD
3.8. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.1.1. Population and Forecast Parameters
4.1.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7MM
4.1.3. Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region
4.1.4. Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region
4.1.5. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in 7MM-2016
4.1.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in 7MM-2027
4.1.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in 7MM-2016
4.1.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in 7MM-2027
4.1.9. Epidemiology of Graft Versus Host Disease
4.2. United States
4.2.1. Assumptions and Rationale
4.2.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States
4.2.3. Diagnosed Incident Cases of Allogeneic HSCT in United States
4.2.4. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in US
4.2.5. Incident cases of aGvHD by Grades in US
4.2.6. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in US
4.2.7. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States
4.2.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States
4.3. EU5
4.3.1. Assumptions and Rationale
4.3.2. Germany
4.3.2.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany
4.3.2.2. Diagnosed Incident Cases of Allogeneic HSCT in Germany
4.3.2.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Germany
4.3.2.4. Incident cases of aGvHD by Grades in Germany
4.3.2.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Germany
4.3.2.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany
4.3.2.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany
4.3.3. France
4.3.3.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France
4.3.3.2. Diagnosed Incident Cases of Allogeneic HSCT in France
4.3.3.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in France
4.3.3.4. Incident cases of aGvHD by Grades in France
4.3.3.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in France
4.3.3.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France
4.3.3.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France
4.3.4. Italy
4.3.4.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy
4.3.4.2. Diagnosed Incident Cases of Allogeneic HSCT in Italy
4.3.4.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Italy
4.3.4.4. Incident cases of aGvHD by Grades in Italy
4.3.4.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Italy
4.3.4.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy
4.3.4.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy
4.3.5. Spain
4.3.5.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain
4.3.5.2. Diagnosed Incident Cases of Allogeneic HSCT in Spain
4.3.5.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Spain
4.3.5.4. Incident cases of aGvHD by Grades in Spain
4.3.5.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Spain
4.3.5.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain
4.3.5.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain
4.3.6. United Kingdom
4.3.6.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom
4.3.6.2. Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom
4.3.6.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in United Kingdom
4.3.6.4. Incident cases of aGvHD by Grades in United Kingdom
4.3.6.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in United Kingdom
4.3.6.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom
4.3.6.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom
4.4. Japan
4.4.1. Assumptions and Rationale
4.4.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
4.4.3. Diagnosed Incident Cases of Allogeneic HSCT in Japan
4.4.4. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Japan
4.4.5. Incident cases of aGvHD by grades in Japan
4.4.6. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Japan
4.4.7. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan
4.4.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan

5. Treatment Algorithm
5.1. Guidelines and Recommendations for Treatment of GvHD
5.2. United States
5.3. Europe
5.4. Japan

6. Unmet Needs

7. Marketed Drugs
7.1. Imbruvica
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Safety and Efficacy of Imbruvica
7.1.6. Side effects of Imbruvica
7.2. Temcell HS
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Safety and Efficacy of Temcell HS
7.2.6. Side effects of Temcell HS
7.3. Grafalon (ATG-Fresenius S)
7.3.1. Product Description
7.3.2. Regulatory Milestones
7.3.3. Advantages and Disadvantages
7.3.4. Product Profile
7.3.5. Safety and Efficacy of Grafalon
7.3.6. Side effects of Grafalon
7.4. Remicade
7.4.1. Product Description
7.4.2. Advantages & Disadvantages
7.4.3. Product Profile
7.4.4. Safety and Efficacy of Remicade
7.4.5. Side effects of Remicade
7.5. Lemtrada
7.5.1. Product Description
7.5.2. Advantages & Disadvantages
7.5.3. Product Profile
7.5.4. Safety and Efficacy of Lemtrada
7.5.5. Adverse reactions of Lemtrada
7.6. Velcade
7.6.1. Product Description
7.6.2. Regulatory Milestones
7.6.3. Advantages & Disadvantages
7.6.4. Product Profile
7.6.5. Safety and Efficacy of Velcade
7.6.6. Side effects of Velcade
7.7. Gleevec
7.7.1. Product Description
7.7.2. Advantages & Disadvantages
7.7.3. Product Profile
7.7.4. Safety and Efficacy of Gleevec
7.7.5. Side effects of Gleevec
7.7.6. SWOT Analysis
7.8. Rapamune
7.8.1. Product Description
7.8.2. Regulatory Milestones
7.8.3. Advantages & Disadvantages
7.8.4. Product Profile
7.8.5. Safety and Efficacy of Rapamune
7.8.6. Adverse reactions of Rapamune
7.8.7. SWOT Analysis
7.9. Simulect
7.9.1. Product Description
7.9.2. Regulatory Milestones
7.9.3. Advantages and Disadvantages
7.9.4. Product Profile
7.9.5. Safety and Efficacy of Simulect
7.9.6. Side effects of Simulect
7.9.7. SWOT Analysis
7.10. Enbrel
7.10.1. Product Description
7.10.2. Advantages and Disadvantages
7.10.3. Product Profile
7.10.4. Safety and Efficacy of Enbrel
7.10.5. Side effects of Enbrel
7.11. Orencia
7.11.1. Product Description
7.11.2. Regulatory Milestones
7.11.3. Advantages and Disadvantages
7.11.4. Product Profile
7.11.5. Safety and Efficacy of Orencia
7.11.6. Side effects of Orencia
7.12. Nulojix
7.12.1. Product Description
7.12.2. Regulatory Milestones
7.12.3. Advantages and Disadvantages
7.12.4. Product Profile
7.12.5. Safety and Efficacy of Nulojix
7.12.6. Side effects of Nulojix

8. Emerging Therapies
8.1. Key Cross Competition
8.2. Therapeutics
8.2.1. Ruxolitinib: Incyte Corporation
8.2.1.1. Product Description
8.2.1.2. Other development activities
8.2.1.3. Clinical Development
8.2.1.4. Clinical Trials Information
8.2.1.5. Safety and Efficacy
8.2.1.6. Advantages and Disadvantages
8.2.1.7. Product Profile
8.2.2. Itacitinib: Incyte Corporation
8.2.2.1. Product Description
8.2.2.2. Other development activities
8.2.2.3. Clinical Development
8.2.2.4. Clinical Trials Information
8.2.2.5. Safety and Efficacy
8.2.2.6. Advantages and Disadvantages
8.2.2.7. Product Profile
8.2.3. Uvadex: Mallinckrodt
8.2.3.1. Product Description
8.2.3.2. Other development activities
8.2.3.3. Clinical Development
8.2.3.4. Clinical Trials Information
8.2.3.5. Safety and Efficacy
8.2.3.6. Advantages and Disadvantages
8.2.3.7. Product Profile
8.2.4. KD025: Kadmon Corporation
8.2.4.1. Product Description
8.2.4.2. Other development activities
8.2.4.3. Clinical Development
8.2.4.4. Clinical Trials Information
8.2.4.5. Safety and Efficacy
8.2.4.6. Advantages and Disadvantages
8.2.4.7. Product Profile
8.2.5. Glassia: Kamada
8.2.5.1. Product Description
8.2.5.2. Other development activities
8.2.5.3. Clinical Development
8.2.5.4. Clinical Trials Information
8.2.5.5. Safety and Efficacy
8.2.5.6. Advantages and Disadvantages
8.2.5.7. Product Profile
8.2.6. Zemiara: CSL Behring
8.2.6.1. Product Description
8.2.6.2. Other development activities
8.2.6.3. Clinical Development
8.2.6.4. Clinical Trials Information
8.2.6.5. Safety and Efficacy
8.2.6.6. Advantages and Disadvantages
8.2.6.7. Product Profile
8.2.7. Leukotac: Elsalys Biotech
8.2.7.1. Product Description
8.2.7.2. Other development activities
8.2.7.3. Clinical Development
8.2.7.4. Clinical Trials Information
8.2.7.5. Safety and Efficacy
8.2.7.6. Advantages and Disadvantages
8.2.7.7. Product Profile
8.3. Prophylaxis
8.3.1. Allocetra: Enlivex Therapeutics
8.3.1.1. Product Description
8.3.1.2. Other development activities
8.3.1.3. Clinical Development
8.3.1.4. Safety and Efficacy
8.3.1.5. Advantages and Disadvantages
8.3.1.6. Product Profile
8.3.2. ATIR101: Kiadis Pharma
8.3.2.1. Product Description
8.3.2.2. Other development activities
8.3.2.3. Clinical Development
8.3.2.4. Clinical Trials Information
8.3.2.5. Safety and Efficacy
8.3.2.6. Advantages and Disadvantages
8.3.2.7. Product Profile

9. Total Market Size of GvHD in 7MM
9.1. 7MM Market Size by Therapies
9.2. United States-GvHD Market
9.2.1. Market Outlook
9.2.2. US Market Size by Therapies
9.2.3. Total Market Size of GVHD in United States
9.2.4. Market Size of Prophylaxis GVHD in United States
9.2.5. Market Size of aGVHD in United States
9.2.6. Market Size of cGVHD in United States
9.3. EU5-GvHD Market
9.3.1. Market Outlook
9.3.2. EU5 Market Size by Therapies
9.3.3. Total Market Size of GVHD in EU5
9.3.4. Germany
9.3.4.1. Total Market Size of GVHD in Germany
9.3.4.2. Market Size of Prophylaxis GVHD in Germany
9.3.4.3. Market Size of aGVHD in Germany
9.3.4.4. Market Size of cGVHD in Germany
9.3.5. France
9.3.5.1. Total Market Size of GVHD in France
9.3.5.2. Market Size of Prophylaxis GVHD in France
9.3.5.3. Market Size of aGVHD in France
9.3.5.4. Market Size of cGVHD in France
9.3.6. Italy
9.3.6.1. Total Market Size of GVHD in Italy
9.3.6.2. Market Size of Prophylaxis GVHD in Italy
9.3.6.3. Market Size of aGVHD in Italy
9.3.6.4. Market Size of cGVHD in Italy
9.3.7. Spain
9.3.7.1. Total Market Size of GVHD in Spain
9.3.7.2. Market Size of Prophylaxis GVHD in Spain
9.3.7.3. Market Size of aGVHD in Spain
9.3.7.4. Market Size of cGVHD in Spain
9.3.8. United Kingdom
9.3.8.1. Total Market Size of GVHD in United Kingdom
9.3.8.2. Market Size of Prophylaxis GVHD in United Kingdom
9.3.8.3. Market Size of aGVHD in United Kingdom
9.3.8.4. Market Size of cGVHD in United Kingdom
9.4. Japan-GvHD Market
9.4.1. Market Outlook
9.4.2. Japan Market Size by Therapies
9.4.3. Total Market Size of GVHD in Japan
9.4.4. Market Size of Prophylaxis GVHD in Japan
9.4.5. Market Size of aGVHD in Japan
9.4.6. Market Size of cGVHD in Japan

10. Market Drivers

11. Market Barriers

12. Appendix

13. Report Methodology

14. Sources Used

15. Consulting Services

16. Disclaimer

17. About the Publisher

List of Tables:
Table 1: Glucksberg Clinical stage of Acute GvHD
Table 2: Glucksberg grade of Acute GvHD
Table 3: Global scoring of cGvHD
Table 4: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7 MM (2016-2027)
Table 5: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027)
Table 6: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region (2016-2027)
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2016-2027)
Table 8: Diagnosed Incident Cases of Allogeneic HSCT in United States in United States (2016-2027)
Table 9: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027)
Table 10: Incident cases of aGvHD by grades in United States (2016-2027)
Table 11: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027)
Table 12: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States (2016-2027)
Table 13: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States (2016-2027)
Table 14: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2016-2027)
Table 15: Diagnosed Incident Cases of Allogeneic HSCT in Germany (2016-2027)
Table 16: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027)
Table 17: Incident cases of aGvHD by grades in Germany (2016-2027)
Table 18: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027)
Table 19: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany (2016-2027)
Table 20: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany (2016-2027)
Table 21: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2016-2027)
Table 22: Diagnosed Incident Cases of Allogeneic HSCT in France (2016-2027)
Table 23: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027)
Table 24: Incident cases of aGvHD by grades in France (2016-2027)
Table 25: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027)
Table 26: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France (2016-2027)
Table 27: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France (2016-2027)
Table 28: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2016-2027)
Table 29: Diagnosed Incident Cases of Allogeneic HSCT in Italy (2016-2027)
Table 30: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027)
Table 31: Incident cases of aGvHD by grades in Italy (2016-2027)
Table 32: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027)
Table 33: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy (2016-2027)
Table 34: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy (2016-2027)
Table 35: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2016-2027)
Table 36: Diagnosed Incident Cases of Allogeneic HSCT in Spain (2016-2027)
Table 37: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027)
Table 38: Incident cases of aGvHD by grades in Spain (2016-2027)
Table 39: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027)
Table 40: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain (2016-2027)
Table 41: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain (2016-2027)
Table 42: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2016-2027)
Table 43: Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom (2016-2027)
Table 44: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027)
Table 45: Incident cases of aGvHD by grades in United Kingdom (2016-2027)
Table 46: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027)
Table 47: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027)
Table 48: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027)
Table 49: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2016-2027)
Table 50: Diagnosed Incident Cases of Allogeneic HSCT in Japan (2016-2027)
Table 51: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027)
Table 52: Incident cases of aGvHD by grades in Japan (2016-2027)
Table 53: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027)
Table 54: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan (2016-2027)
Table 55:5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan (2016-2027)
Table 56: GVHD Prophylaxis regimen for Reduced intensity conditioning
Table 57: Comparison of emerging drugs under development for treatment
Table 58: Comparison of emerging drugs under development for prophylaxis
Table 59: Ruxolitinib Clinical Trial Description, 2017
Table 60: Itacitinib Clinical Trial Description, 2017
Table 61: Uvadex Clinical Trial Description, 2017
Table 62: KD025 Clinical Trial Description, 2017
Table 63: Glassia Clinical Trial Description, 2017
Table 64: Zemaira Clinical Trial Description, 2017
Table 65: Zemaira Clinical Trial Description, 2017
Table 66: ATIR101 Clinical Trial Description, 2017
Table 4: Total Market Size of GvHD in 7MM, in USD Millions (2016-2027)
Table 67: 7MM Market Size of GvHD by Therapies in USD, Million (2016-2027)
Table 68: US Market Size of GvHD by Therapies in USD, Million (2016-2027)
Table 69: Total Market Size of GVHD in United States in USD, Million (2016-2027)
Table 70: Market Size of Prophylaxis GVHD in United States in USD, Million (2016-2027)
Table 71: Market Size of aGVHD in United States in USD, Million (2016-2027)
Table 72: Market Size of cGVHD in United States in USD, Million (2016-2027)
Table 73: EU5 Market Size of GvHD by Therapies in USD, Million (2016-2027)
Table 74: Total Market Size of GVHD in EU5 in USD, Million (2016-2027)
Table 75: Total Market Size of GVHD in Germany in USD, Million (2016-2027)
Table 76: Market Size of Prophylaxis GVHD in Germany in USD, Million (2016-2027)
Table 77: Market Size of aGVHD in Germany in USD, Million (2016-2027)
Table 78: Market Size of cGVHD in Germany in USD, Million (2016-2027)
Table 79: Total Market Size of GVHD in France in USD, Million (2016-2027)
Table 80: Market Size of Prophylaxis GVHD in France in USD, Million (2016-2027)
Table 81: Market Size of aGVHD in France in USD, Million (2016-2027)
Table 82: Market Size of cGVHD in France in USD, Million (2016-2027)
Table 83: Total Market Size of GVHD in Italy in USD, Million (2016-2027)
Table 84: Market Size of Prophylaxis GVHD in Italy in USD, Million (2016-2027)
Table 85: Market Size of aGVHD in Italy in USD, Million (2016-2027)
Table 86: Market Size of cGVHD in Italy in USD, Million (2016-2027)
Table 87: Total Market Size of GVHD in Spain in USD, Million (2016-2027)
Table 88: Market Size of Prophylaxis GVHD in Spain in USD, Million (2016-2027)
Table 89: Market Size of aGVHD in Spain in USD, Million (2016-2027)
Table 90: Market Size of cGVHD in Spain in USD, Million (2016-2027)
Table 91: Total Market Size of GVHD in United Kingdom in USD, Million (2016-2027)
Table 92: Market Size of Prophylaxis GVHD in United Kingdom in USD, Million (2016-2027)
Table 93: Market Size of aGVHD in United Kingdom in USD, Million (2016-2027)
Table 94: Market Size of cGVHD in United Kingdom in USD, Million (2016-2027)
Table 95: Japan Market Size of GvHD by Therapies in USD, Million (2016-2027)
Table 96: Total Market Size of GVHD in Japan in USD, Million (2016-2027)
Table 97: Market Size of Prophylaxis GVHD in Japan in USD, Million (2016-2027)
Table 98: Market Size of aGVHD in Japan in USD, Million (2016-2027)
Table 99: Market Size of cGVHD in Japan in USD, Million (2016-2027)

List of Figures:
Figure 1: Pathophysiology of GvHD
Figure 2: Risk Factors for GvHD
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7 MM (2016-2027)
Figure 4: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027)
Figure 5: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027)
Figure 6: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2016-2027)
Figure 7: Diagnosed Incident Cases of Allogeneic HSCT in United States (2016-2027)
Figure 8: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027)
Figure 9: Incident cases of aGvHD by grades in United States (2016-2027)
Figure 10: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027)
Figure 11: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States (2016-2027)
Figure 12: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States (2016-2027)
Figure 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2016-2027)
Figure 14: Diagnosed Incident Cases of Allogeneic HSCT in Germany (2016-2027)
Figure 15: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027)
Figure 16: Incident cases of aGvHD by grades in Germany (2016-2027)
Figure 17: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027)
Figure 18: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany (2016-2027)
Figure 19: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany (2016-2027)
Figure 20: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2016-2027)
Figure 21: Diagnosed Incident Cases of Allogeneic HSCT in France (2016-2027)
Figure 22: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027)
Figure 23: Incident cases of aGvHD by grades in France (2016-2027)
Figure 24: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027)
Figure 25: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France (2016-2027)
Figure 26: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France (2016-2027)
Figure 27: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2016-2027)
Figure 28: Diagnosed Incident Cases of Allogeneic HSCT in Italy (2016-2027)
Figure 29: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027)
Figure 30: Incident cases of aGvHD by grades in Italy (2016-2027)
Figure 31: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027)
Figure 32: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy (2016-2027)
Figure 33: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy (2016-2027)
Figure 34: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2016-2027)
Figure 35: Diagnosed Incident Cases of Allogeneic HSCT in Spain (2016-2027)
Figure 36: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027)
Figure 37: Incident cases of aGvHD by grades in Spain (2016-2027)
Figure 38: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027)
Figure 39: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain (2016-2027)
Figure 40: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain (2016-2027)
Figure 41: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2016-2027)
Figure 42: Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom (2016-2027)
Figure 43: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027)
Figure 44: Incident cases of aGvHD by grades in United Kingdom (2016-2027)
Figure 45: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027)
Figure 46: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027)
Figure 47: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027)
Figure 48: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2016-2027)
Figure 49: Diagnosed Incident Cases of Allogeneic HSCT in Japan (2016-2027)
Figure 50: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027)
Figure 51: Incident cases of aGvHD by grades in Japan (2016-2027)
Figure 52: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027)
Figure 53: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan (2016-2027)
Figure 54:5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan (2016-2027)
Figure 55: Treatment algorithm for GvHD
Figure 56: GVHD Prophylaxis regimen for Myeloablative conditioning
Figure 3: Total Market Size of GvHD in 7MM, in USD Millions (2016-2027)
Figure 57: 7MM Market Size of GvHD by Therapies in USD, Million (2016-2027)
Figure 58: US Market Size of GvHD by Therapies in USD, Million (2016-2027)
Figure 59: Total Market Size of GVHD in United States in USD, Million (2016-2027)
Figure 60: Market Size of Prophylaxis GVHD in United States in USD, Million (2016-2027)
Figure 61: Market Size of aGVHD in United States in USD, Million (2016-2027)
Figure 62: Market Size of cGVHD in United States in USD, Million (2016-2027)
Figure 63: EU5 Market Size of GvHD by Therapies in USD, Million (2016-2027)
Figure 64: Total Market Size of GVHD in EU5 in USD, Million (2016-2027)
Figure 65: Total Market Size of GVHD in Germany in USD, Million (2016-2027)
Figure 66: Market Size of Prophylaxis GVHD in Germany in USD, Million (2016-2027)
Figure 67: Market Size of aGVHD in Germany in USD, Million (2016-2027)
Figure 68: Market Size of cGVHD in Germany in USD, Million (2016-2027)
Figure 69: Total Market Size of GVHD in France in USD, Million (2016-2027)
Figure 70: Market Size of Prophylaxis GVHD in France in USD, Million (2016-2027)
Figure 71: Market Size of aGVHD in France in USD, Million (2016-2027)
Figure 72: Market Size of cGVHD in France in USD, Million (2016-2027)
Figure 73: Total Market Size of GVHD in Italy in USD, Million (2016-2027)
Figure 74: Market Size of Prophylaxis GVHD in Italy in USD, Million (2016-2027)
Figure 75: Market Size of aGVHD in Italy in USD, Million (2016-2027)
Figure 76: Market Size of cGVHD in Italy in USD, Million (2016-2027)
Figure 77: Total Market Size of GVHD in Spain in USD, Million (2016-2027)
Figure 78: Market Size of Prophylaxis GVHD in Spain in USD, Million (2016-2027)
Figure 79: Market Size of aGVHD in Spain in USD, Million (2016-2027)
Figure 80: Market Size of cGVHD in Spain in USD, Million (2016-2027)
Figure 81: Total Market Size of GVHD in United Kingdom in USD, Million (2016-2027)
Figure 82: Market Size of Prophylaxis GVHD in United Kingdom in USD, Million (2016-2027)
Figure 83: Market Size of aGVHD in United Kingdom in USD, Million (2016-2027)
Figure 84: Market Size of cGVHD in United Kingdom in USD, Million (2016-2027)
Figure 85: Japan Market Size of GvHD by Therapies in USD, Million (2016-2027)
Figure 86: Total Market Size of GVHD in Japan in USD, Million (2016-2027)
Figure 87: Market Size of Prophylaxis GVHD in Japan in USD, Million (2016-2027)
Figure 88: Market Size of aGVHD in Japan in USD, Million (2016-2027)
Figure 89: Market Size of cGVHD in Japan in USD, Million (2016-2027)
Figure 90: Market Drivers
Figure 91:Market Barriers

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • CSL Behring
  • Enlivex Therapeutics
  • Incyte Corportaion
  • Kamada
  • Mallinckrodt
  • MORE

Graft versus Host Disease (GvHD) - Disease Understanding and Treatment Algorithm

The Graft versus Host Disease (GvHD) market report gives the thorough understanding of the Graft versus Host Disease (GvHD) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Graft versus Host Disease (GvHD) in the US, Europe, and Japan.

Graft versus Host Disease (GvHD) Epidemiology

The Graft versus Host Disease (GvHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]. The epidemiology section of report further includes diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs). It also includes diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs.

The diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) in 7 major markets was 53,601 (which includes 21,408 Incident cases of first allogeneic HSCT) in 2016 and, is expected to increase during the study period i.e., 2016-2027. Among 7MM United States account for highest diagnosed incident cases of aGvHD and cGvHD in diagnosed incident cases of First Allogeneic HSCTs followed by Germany.

Graft versus Host Disease (GvHD) Drug Chapters

This segment of the Graft versus Host Disease (GvHD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Presently, the GvHD market comprises of majorly off-label drugs. Off-label drugs used in treatment and prevention of GvHD includes Corticosteroids (methylprednisolone and prednisolone), Calcineurin inhibitors (Cyclosporine), IL2Ra (CD25) inhibitors (Simulect), TNFa inhibitors (Remicade and Enbrel), Co-stimulatory blockers (Orencia and Nulojix), mTOR inhibitors (Rapamune and Certican), SOT therapies (CellCept/Myfortic and Prograf), Anti-neoplastic therapies (Velcade, Gleevec, Methotrexate, Nipent and Cyclophosphamide) and other biologics (Lemtrada and Rituxan/MabThera).

Currently there are three approved therapies for GvHD including Imbruvica (in US for cGvHD), Remestemcel-L (in Japan for aGvHD) and Grafalon (in Germany for prophylaxis of GvHD). Detailed chapters for all of these drugs, along with the promising upcoming therapies have been covered in the report.

Graft versus Host Disease (GvHD) Market Outlook

The Graft versus Host Disease (GvHD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

GvHD market size is segmented into Prophylaxis and Therapeutics. Therapeutics section is further subcategorized into aGvHD and cGvHD. The 7MM market of Graft versus Host Disease (GvHD) was USD 353.5 million in 2016, and is expected to increase at a CAGR from 2016-2027.

Graft versus Host Disease (GvHD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The market size of Graft versus Host Disease (GvHD) includes the drug-uptake for individual therapies, which is further segmented which is further segmented in prophylaxis and therapeutics.

Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Amgen
  • Bristol Myers Squibb/ Ono Pharmaceuticals, Co. Ltd
  • CSL Behring
  • Elsalys Biotech
  • Enlivex Therapeutics
  • Genzyme Corporation
  • Incyte Corportaion
  • Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.)
  • JCR Pharmaceuticals Co., Ltd.
  • Kadmon Corporation
  • Kamada
  • Kiadis Pharma
  • Mallinckrodt
  • Neovii Biotech
  • Novartis
  • Takeda Pharmaceutical Company Limited
  • Wyeth Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll